Innovative Drug CRO Market Size, Share & Industry Analysis, By Service Type (Drug Discovery, Preclinical Development, Clinical Development, and Regulatory Affairs), By Development Stage (Preclinical, Phase I, Phase II, Phase III, and Post-Approval), By Drug Modality (Small-Molecule, Biologics, Cell Therapies, and Gene Therapies), By Therapeutic Area (Oncology, Neurology, Cardiovascular, and Immunology), By Outsourcing Model (Full-Service, Functional Service Provider, and Hybrid), By Sponsor Type (Large Biopharma, Small Biopharma, and Academic Institutes), and Regional Forecast, 2026-2034

Last Updated: August 12, 2026 | Format: PDF | Report ID: FBI118865

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 7.6% from 2026-2034
Unit	Value (USD Billion)
Segmentation	By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Region
By Service Type	Drug Discovery Services Target Identification & Validation Assay Development & High-Throughput Screening Lead Optimization Others Preclinical Development Services In-vitro Testing Toxicology & Safety Assessment Others Clinical Development Services Site Identification, Selection & Management Clinical Monitoring Project & Vendor Management Others Laboratory & Bioanalytical Services Data Management & Medical Writing Regulatory Affairs Services Safety & Pharmacovigilance Services Real-World Evidence & Late-Phase Services
By Development Stage	Drug Discovery Preclinical Development Phase I Phase II Phase III Post-Approval / Phase IV
By Drug Modality	Small-Molecule Drugs Biologics Cell Therapies Autologous Cell Therapies Allogeneic Cell Therapies Other Cell Therapies Gene Therapies In-vivo Gene Therapies Ex-vivo Gene Therapies RNA-Based Therapeutics Others
By Therapeutic Area	Oncology Neurology & CNS Disorders Cardiovascular Diseases Metabolic & Endocrine Disorders Immunology & Autoimmune Diseases Infectious Diseases Respiratory Diseases Others
By Outsourcing Model	Full-Service Outsourcing Functional Service Provider Outsourcing Hybrid / Strategic Outsourcing
By Sponsor Type	Large Biopharmaceutical Companies Small & Mid-Sized Biopharmaceutical Companies Academic & Research Institutions Others
By Region	North America (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country) U.S. By Service Type Canada By Service Type Europe (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country/Sub-region) Germany By Service Type U.K. By Service Type France By Service Type Spain By Service Type Italy By Service Type Scandinavia By Service Type Rest of Europe By Service Type Asia Pacific (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country/Sub-region) China By Service Type Japan By Service Type India By Service Type Australia By Service Type Southeast Asia By Service Type Rest of Asia Pacific By Service Type Latin America (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country/Sub-region) Brazil By Service Type Mexico By Service Type Rest of Latin America By Service Type Middle East & Africa (By Service Type, Development Stage, Drug Modality, Therapeutic Area, Outsourcing Model, Sponsor Type, and Country/Sub-region) GCC By Service Type South Africa By Service Type Rest of Middle East & Africa By Service Type